<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="covidseq/PMC7172913/results/search/disease/results.xml">
  <result pre="doi: 10.1016/S1473-3099(20)30248-6 : Article Safety and immunogenicity of a modified" exact="vaccinia virus" post="Ankara vector vaccine candidate for Middle East respiratory syndrome:"/>
  <result pre="Background The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a" exact="respiratory disease" post="with a case fatality rate of up to 35%."/>
  <result pre="aimed to assess safety and tolerability of an anti-MERS-CoV modified" exact="vaccinia virus" post="Ankara (MVA)-based vaccine candidate that expresses the MERS-CoV spike"/>
  <result pre="MVA-MERS-S, a novel vaccine candidate based on the recombinant modified" exact="vaccinia virus" post="Ankara (MVA) vaccine vector platform, has been reported to"/>
  <result pre="for protection. In this study, we used the recombinant modified" exact="vaccinia virus" post="Ankara (rMVA) vaccine vector platform, which has been shown"/>
  <result pre="sequence. A phytohemagglutinin pool and a cytomegalovirus, Epstein-Barr virus, and" exact="influenza" post="peptide pool (JPT Peptide Technologies, Berlin, Germany) served as"/>
  <result pre="in the appendix (p 9). MERS=Middle East respiratory syndrome. MVA=modified" exact="vaccinia virus" post="Ankara. PFU=plaque-forming unit. S=spike. *One participant had to move"/>
  <result pre="dropped out received no booster immunisation because of an unrelated" exact="urinary tract infection" post="on day 27. This person was not replaced at"/>
  <result pre="MVA-MERS-S in each dose group. MERS=Middle East respiratory syndrome. MVA=modified" exact="vaccinia virus" post="Ankara. S=spike. Solicited local reactions were the most common"/>
  <result pre="the low-dose and high-dose groups. MERS=Middle East respiratory syndrome. MVA=modified" exact="vaccinia virus" post="Ankara. S=spike. Table 2 Haematological changes Low-dose group (n=14)"/>
  <result pre="immune absorbent spot assay. MERS-CoV=Middle East respiratory syndrome coronavirus. MVA=modified" exact="vaccinia virus" post="Ankara. RBD=receptor binding domain. S=spike. SFCs=spot-forming cells. PBMCs=peripheral blood"/>
  <result pre="to those observed in a phase 1 trial testing the" exact="influenza" post="vaccine MVA-H5-sfMR, 18 in which participants received the same"/>
  <result pre="context of MERS-CoV infections, which has been previously discussed for" exact="severe acute respiratory syndrome" post="(SARS) coronavirus. 29 Future studies in animal models, possibly"/>
  <result pre="RAM Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia N Engl J Med 367 2012"/>
  <result pre="Middle East respiratory syndrome coronavirus spike protein delivered by modified" exact="vaccinia virus" post="Ankara efficiently induces virus-neutralizing antibodies J Virol 87 2013"/>
  <result pre="984 992 30060038 11 Gilbert SC Clinical development of modified" exact="vaccinia virus" post="Ankara vaccines Vaccine 31 2013 4241 4246 23523410 12"/>
  <result pre="2013 4241 4246 23523410 12 Volz A Sutter G Modified" exact="vaccinia virus" post="Ankara: history, value in basic research, and current perspectives"/>
  <result pre="A Kupke A Song F Protective efficacy of recombinant modified" exact="vaccinia virus" post="Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein"/>
  <result pre="Goeijenbier M Moesker FM Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based" exact="influenza" post="A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical"/>
 </snippets>
</snippetsTree>
